Physician profile
David W Mudd
NPI 1750376794
$5,666.77
in general payments reported to CMS, 2019-2025
34 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $584 · 2021: $256 · 2022: $587 · 2023: $1,206 · 2024: $1,298 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,021.01 | 2019-2025 | |
| Abbvie INC. | $803.00 | 2020-2024 | |
| Novo Nordisk INC | $666.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $425.91 | 2019-2024 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $389.18 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $352.47 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $291.02 | 2019-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $274.20 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.79 | 2019-2022 | |
| Abbott Laboratories | $153.97 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $120.60 | 2019-2023 | Vaxneuvance, Pneumovax 23, M-M-R II |
| Shield Therapeutics INC | $117.38 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $107.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.43 | 2023 | Xarelto |
| Boston Scientific Corporation | $96.89 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $80.46 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $64.21 | 2023-2024 | Nuzyra |
| Exact Sciences Corporation | $54.71 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.09 | 2023-2024 | Xifaxan |
| Daiichi Sankyo INC. | $43.22 | 2022-2023 | Injectafer |
| Eisai INC. | $29.99 | 2024 | |
| Lucid Diagnostics INC. | $26.61 | 2024 | |
| Phathom Pharmaceuticals, INC. | $23.86 | 2024 | Voquezna |
| Biogen, INC. | $23.55 | 2024 | Leqembi |
| Scilex Pharmaceuticals INC. | $22.27 | 2019 | |
| Idorsia Pharmaceuticals US INC | $20.66 | 2023 | Quviviq |
| Rgh Enterprises LLC | $20.10 | 2025 | |
| Philips North America LLC | $20.01 | 2020 | |
| Amarin Pharma, INC. | $19.06 | 2019 | |
| Medtronic, INC. | $18.66 | 2023 | Inpen Smart Insulin Delivery System |
| Bridgebio Pharma, INC. | $18.09 | 2025 | Attruby |
| Dynavax Technologies Corporation | $17.83 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $15.82 | 2019 | |
| Dexcom, INC. | $15.28 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.